Skip to main content

Advertisement

Table 2 Adverse Events in Pazopanib Recipients by Age Subgroups (Safety Population)

From: Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses

Events, n (%) Age < 65 Years (n = 180) Age ≥ 65 Years (n = 60)
Any on-therapy AE 178 (99) 59 (98)
AEs related to study treatment 168 (93) 51 (85)
AEs leading to permanent discontinuation or early withdrawal 30 (17) 18 (30)
AEs leading to dose reduction 60 (33) 17 (28)
AEs leading to dose interruption/delay 89 (49) 31 (52)
Any SAE 75 (42) 24 (40)
SAEs related to study treatment 40 (22) 17 (28)
Fatal SAEs 7 (4) 1 (2)
Fatal SAEs related to study treatment 1 (< 1) 0 (0)
  1. AE adverse event, SAE serious adverse event.